# EDGAR Filing Document

**Accession Number:** 0002048877
**File Stem:** 0001213900-25-085390
**Filing Date:** 2025-9
**Character Count:** 2826
**Document Hash:** bb4f6f1ed62e0289eca5c3663cfb85fc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-085390.hdr.sgml**: 20250908

**ACCESSION NUMBER**: 0001213900-25-085390

**CONFORMED SUBMISSION TYPE**: 15-15D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250908

**DATE AS OF CHANGE**: 20250908

**EFFECTIVENESS DATE**: 20250908

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YD Biopharma Ltd
- **CENTRAL INDEX KEY:** 0002048877
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-15D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-283428-01
- **FILM NUMBER:** 251299131

**BUSINESS ADDRESS:**
- **STREET 1:** 12F., NO. 3, XINGNAN ST.
- **STREET 2:** NANGANG DIST.
- **CITY:** TAIPEI CITY
- **STATE:** F5
- **ZIP:** 115001
- **BUSINESS PHONE:** 88623820030

**MAIL ADDRESS:**
- **STREET 1:** 12F., NO. 3, XINGNAN ST.
- **STREET 2:** NANGANG DIST.
- **CITY:** TAIPEI CITY
- **STATE:** F5
- **ZIP:** 115001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission File Number: 333-283428-01

**YD BIOPHARMA LIMITED**

(Exact name of registrant as specified in its charter)

**12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan**

**+(886) 2382-0330**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Ordinary shares, par value $0.10 per share**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: **One**

Pursuant to the requirements of the Securities Exchange Act of 1934, YD Biopharma Limited has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **YD Biopharma Limited** | **YD Biopharma Limited** |
| Date: September 8, 2025 |  |  |
|  | By: | /s/ Ethan Shen |
|  | Name: | Ethan Shen |
|  | Title: | Chief Executive Officer |

---